Intermittent androgen deprivation for locally advanced prostate cancer: Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

Oncology

Volumn 65, Issue SUPPL. 1, 2003, Pages 24-28

  Da Silva, Fernando Calais ^a   Bono, A ^b   Whelan, P ^c   Brausi, M ^d   Queimadelos, M ^e   Portillo, J ^f   Kirkali, Z ^g   Robertson, C ^h  

^a Hospital do Desterro   (Portugal)

^b OSPEDALE DI CIRCOLO   (Italy)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d Estensis Hospital   (Italy)

^e Policlínico La Rosadela   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g DOKUZ EYLUL UNIVERSITY   (Turkey)

^h UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FOLLOW UP; HORMONAL THERAPY; HUMAN; IMPOTENCE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE II; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0042914929     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072488     Document Type: Article

References (8)

1. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lowson D: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275-2282.
2. Louis D, Murphy GP: Overview of phase III trials on combined androgen treatment in patients with metastatic prostatic cancer. Cancer 1993;72(suppl):3888-3895.
3. Vahlensieck W, Wegner G, Lehmann HD, Frazen G, Steffens L, Wählby S: Comparison between continuous and intermittent administration of Estracyt in the treatment of carcinoma of the prostate. Urol Res 1985;13:209-212.
4. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr: Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546-2550.
5. Theyer G, Hamilton G: Current status of intermittent androgen suppression in the intermittent treatment of prostate cancer. Urology 1998;52:353-359.
6. Bruchovsky N, Klotz LH, Crook JM, Armitage GR, Gleave ME: A phase II study of intermittent androgen suppression in men with a rising PSA after radiation for localized prostate cancer. J Urol 1998;159:A1287.
7. Goldenberg SL, et al: Intermittent androgen suppression in treatment of prostate cancer. A preliminary report. Urology 1995;45:839-845.
8. Gleave ME, Bruchovsky N, Goldenberg SL, Rennie P: Intermittent androgen suppression: Rationale and clinical experience; in Schroeder F (ed): Recent Advances in Prostate Cancer and BPH. London, Parthenon Publishing, 1997, pp 109-121.